PRAC Finds Inconsistent Evidence on Paternal Valproate Neurodevelopmental Risk, Maintains Precautionary Measures
核心洞察
The EMA's PRAC (搜索) concluded that evidence linking paternal valproate exposure to neurodevelopmental disorders (搜索) in offspring is inconsistent and a causal role remains uncertain.
Precautionary measures introduced in 2024 for male patients will remain in place pending results of an ongoing larger study expected to conclude in 2028.
Product information, healthcare professional guides, and male patient guides will be updated to reflect the most recent data.
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC (搜索)) has completed its review of a safety signal concerning valproate and related substances, concluding that the evidence on neurodevelopmental disorders (搜索) (NDDs) in children born to men treated with valproate is inconsistent and the causal role of valproate is uncertain. The committee's findings, published on June 12, 2026, following the PRAC session of June 8–11, represent the formal terminus of an evaluation cycle that has been underway since 2018.
"The evidence on neurodevelopmental disorders (搜索) (NDDs) in children born to men treated with valproate is inconsistent and a causal role of valproate is uncertain," the PRAC (搜索) stated in its meeting highlights. This formulation carries significant regulatory weight: under the GVP Module IX signal management guideline, a signal that cannot be confirmed or refuted after structured evaluation requires action, but the proportionality of any measure must reflect the evidentiary uncertainty.
The Underlying Data and Methodological Challenges
The PRAC (搜索)'s review was anchored in study EUPAS34201, a retrospective observational study commissioned by the EMA in 2018 and conducted across registry databases in Denmark, Sweden, and Norway. While findings from one study suggested a possible link between valproate and NDDs, most retrospective observational studies investigating this issue have not found an increased risk of NDDs.
A central methodological challenge identified by the committee is confounding by indication. Men prescribed valproate carry underlying neurological or psychiatric diagnoses — epilepsy (搜索), bipolar disorder (搜索) — that are themselves associated with elevated neurodevelopmental risk in offspring through genetic transmission. As the PRAC (搜索) noted, "most retrospective observational studies in this area have methodological limitations, including confounding by indication, which makes it difficult to establish causality." The limitation is structural, not a matter of sample size.
This stands in marked contrast to the maternal exposure picture. A systematic review and meta-analysis found gestational valproate exposure associated with an adjusted hazard ratio of 3.10 for autism spectrum disorder in offspring — a signal so large and consistent that it drove the comprehensive pregnancy prevention program established by the EMA and CMDh in 2018. The paternal signal has never approached that magnitude or consistency.
Precautionary Measures Maintained, Not Escalated
In January 2024, following assessment of a post-authorisation safety study (PASS) using data from multiple registry databases in Denmark, Norway, and Sweden, the PRAC (搜索) concluded that NDDs are a potential risk in children born to men treated with valproate during the three months before conception and recommended precautionary measures. At that time, the committee also requested marketing authorisation holders to carry out a larger study specifically designed to address the PASS study's limitations; this study is ongoing and expected to conclude in 2028.
The latest safety signal was initiated in July 2025 after publication of a Danish nationwide registry-based study that did not suggest an increased risk of NDDs in children born to men treated with valproate. In assessing this signal, PRAC (搜索) reviewed all the latest evidence and could not conclude whether a potential risk is due to valproate or other factors, such as the fathers' underlying medical condition.
Despite the uncertainty, the PRAC (搜索) recommended that the precautionary measures introduced in 2024 remain in place. The committee also recommended updating the product information, the healthcare professional guide, and the guide for male patients to ensure access to the most up-to-date information.
Calibrating the Regulatory Response
The PRAC (搜索)'s response to paternal exposure risk reveals a carefully calibrated regulatory approach. The maternal pregnancy prevention program includes a mandatory annual risk acknowledgment form, specialist-only prescribing initiation, and a formal contraindication in women of childbearing potential not enrolled in the prevention program. By contrast, the paternal measure consists of a product information update and a recommendation that men planning to father a child discuss this with their doctor.
This calibration reflects the precautionary architecture of European pharmacovigilance regulation: under Article 116 of Directive 2001/83/EC, a risk-benefit balance can justify label changes even when the evidentiary standard for causation has not been met, provided the potential harm is serious and the mitigation measure is proportionate. Labeling updates and healthcare professional communications carry a lower proportionality threshold than contraindications or mandatory risk minimization programs.
A product information update triggers a Type II variation application under Regulation (EC) No 1234/2008 for centrally authorized products, or an equivalent national variation for decentralized authorizations. The administrative burden is real, but the measure does not constrain prescribing volumes for male patients the way the 2018 maternal measures constrained female prescribing.
Implications for Clinical Practice
Healthcare professionals are expected to proactively discuss the potential risk with men of reproductive age treated with valproate who are planning to father a child, and this discussion should be documented. The documentation requirement transforms an advisory communication into a medical record obligation, creating a traceable audit trail around counseling conversations that previously had no formal documentation standard.
Valproate medicines are used to treat epilepsy (搜索) and bipolar disorder (搜索), and in some EU Member States are also authorised to prevent migraine headaches. NDDs encompass problems with development that begin in early childhood, such as autism spectrum disorders (搜索), intellectual disability, communication disorders, attention deficit/hyperactivity disorders, and movement disorders.
The PRAC (搜索) did not close the signal. It acted on it at the level the evidence supports while leaving the causal question explicitly open. Sponsors should expect this signal to be reassessed as new registry data matures and as the ongoing larger study approaches its 2028 conclusion. The documentation requirement for healthcare professional conversations will itself generate a structured dataset over the next several years — one that could eventually help resolve the confounding-by-indication problem through better captured baseline information.